Head-to-head · free
BioStem Technologies, Inc. vs Quest Diagnostics
BSEM vs DGX — return on capital, cash generation, margins and balance sheet side by side.
BSEM
0 / 0
measures where BSEM leads
DGX
0 / 0
measures where DGX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | BSEM | DGX · FY2025 |
|---|---|---|
| Revenue | — | $11.0B |
| Net income | — | $992.0M |
| Revenue growth (yearly, multi-year) | — | 0.6% |
| Free cash flow | — | $1.4B |
| Free cash flow margin | — | 12.3% |
| Net cash / (debt) | — | — |
| ROIC | — | 8.5% |
| Return on equity | — | 14.2% |
| Gross margin | — | 33.2% |
| Operating margin | — | 14.1% |
| Net debt / EBITDA | — | 2.57x |
Figures are as reported by each company; latest fiscal year shown.
Where Quest Diagnostics's cash went (FY2025)
- Capital spending
- $527.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free